ATOS icon

Atossa Therapeutics
ATOS

12 hedge funds and large institutions have $775K invested in Atossa Therapeutics in 2015 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

0.2% less ownership

Funds ownership: 3.52% → 3.31% (-0.2%)

14% less funds holding

Funds holding: 14 → 12 (-2)

32% less capital inflows, than outflows

Capital inflows: $61.6K | Capital outflows: $90.5K

50% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 4

Holders
12
Holders Change
-2
Holders Change %
-14.29%
% of All Funds
0.33%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
2
Reduced
2
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
+$30.8K
2
UBS Group
UBS Group
Switzerland
+$12.8K
3
Vanguard Group
Vanguard Group
Pennsylvania
+$12.8K
4
Northern Trust
Northern Trust
Illinois
+$5.13K

Top Sellers

Rank Fund Capital Flow
1
VKH
Virtu KCG Holdings
New York
-$59K
2
FCCM
First City Capital Management
Georgia
-$20.3K
3
Citigroup
Citigroup
New York
-$4K
4
BFA
BlackRock Fund Advisors
California
-$2.57K
5
Wells Fargo
Wells Fargo
California
-$2.57K

ATOS Hedge Fund Activity: Q3 2015 in Review

12 of the 3,590 institutional investors tracked by Wall St. Rank reported a position in Atossa Therapeutics (ATOS) for Q3 2015, worth a combined $775K — down 33% from $1.15M a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of ATOS and 2 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 2 added.

The largest buyer was Goldman Sachs, opening a new position worth an estimated $30.8K. The largest seller was Virtu KCG Holdings, exiting entirely with an estimated $59K sold.

  • 12 institutional investors held Atossa Therapeutics (ATOS) as of Q3 2015, down from 14 in Q2 2015.
  • Funds reported $775K of Atossa Therapeutics stock for Q3 2015, down 33% quarter-over-quarter.
  • 2 funds opened new Atossa Therapeutics positions in Q3 2015 and 4 closed out, a net change of -2 holders.
  • The largest Atossa Therapeutics buyer in Q3 2015 was Goldman Sachs, an estimated $30.8K added.
  • The largest Atossa Therapeutics seller in Q3 2015 was Virtu KCG Holdings, an estimated $59K sold.

Based on aggregated 13F filings for Q3 2015.